Tea Zeppola

Date of birth: Novembr 8, 1989

Nationality: Italian

• From 2019: PhD student, Campus Bio-Medico University Hospital

• 2021: Specialized in Medical Oncology, University Campus Bio-Medico of Rome - Italy, 50/50 cum laude

• 2015: Italian Licence to practice Medicine and Surgery (second session of the 2015 State Examination)

• 2014: Graduated with honors in Medicine and Surgery,

University Campus Bio-Medico of Rome - Italy, 110/110 cum laude.

• Attending the third year of the PHD in ethical and biomedical sciences with an osteo-oncology curriculum

1. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2014 Dec;92(3):208-17. doi: 10.1016/j.critrevonc.2014.07.006. Epub 2014 Aug 6. PMID: 25151214 2. . Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Crit Rev Oncol Hematol. 2017 Jul; 115:1-12. PMID: 28602164- 3. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004. PMID: 29324972

4.. Clinical Outcomes of Patients with Advanced Cancer and Pre- Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study Oncologist. 2019 Jun; 24(6):e327-e337. doi: 10.1634/theoncologist.2018-0618. Epub 2019 Feb 22. PMID: 30796151-5. . A multicenter study of body mass index in cancer patients treated with anti-PD- 1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.PMID: 30813970-6. . Correlations Between the Immune-related Adverse Events Spectrum and

7.Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clin Lung Cancer. 2019 Jul; 20(4):237-247.e1. doi: 10.1016/j.cllc.2019.02.006. Epub 2019 Feb 21. PMID: 30885550

8.. Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. J Transl Med. 2019 Nov 15;17(1):376. doi: 10.1186/s12967-019-02132-x. PMID: 31730009

9 C. Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. Oncoimmunology. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389. eCollection 2020.PMID: 32002308

10. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer. 2020 Mar;128:17-26. doi: 10.1016/j.ejca.2019.12.031. Epub 2020 Mar 5. PMID: 32109847

10.Prognostic and predictive factors in pancreatic cancer. Oncotarget. 2020 Mar 10;11(10):924-941. doi: 10.18632/oncotarget.27518. eCollection 2020 Mar 10. PMID: 32206189

11.Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? Clin Med Insights Oncol. 2020 Aug 4;14:1179554920946693. doi: 10.1177/1179554920946693. eCollection 2020.

12. Denosumab for cancer-related bone loss. Expert Opin Biol Ther. 2020 Nov;20(11):1261-1274. doi: 10.1080/14712598.2020.1814731. Epub 2020 Sep 9.

13. Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the

IOPS-MS Study. JCO Precis Oncol. 2020 Nov 4;4:PO.20.00158. doi: 10.1200/PO.20.00158. eCollection 2020.PMID: 33283139

14. . PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. J Transl Med. 2021 Jun 24;19(1):270. doi: 10.1186/s12967-021-02937-9.PMID: 34167578

15. Efficacia in II linea del trattamento con capecitabina e lapatinib nella neoplasia mammaria HER2-positiva, con metastasi encefaliche, dopo I linea con doppio blocco anti-HER2. Raccolta di casi clinici pubblicati su Aboutopen 2017-2018